Traitement systémique des métastases cérébrales de mélanome

Rhun, Émilie Le; Mateus, Christine; Mortier, Laurent; Dhermain, Frédéric; Guillot, B.; Grob, Jean-Jacques; Lebbe, Célèste; Thomas, Marina; Jouary, Thomas; Leccia, Marie‐Thérèse; Robert, Caroline

doi:10.1016/j.canrad.2014.11.010

Cited by 3 publications

(2 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prognosis of patients with MBM is poor with a mean survival of 3-6 months; in patients treated solely with corticosteroids, the mean survival is 2 months, whilst after the whole brain radiotherapy (WBRT) -it is about 3-4 months [6,8,10,[12][13][14][15][16]. Numerous publication data suggests that some patients may benefit from surgical treatment or radio-surgery (with the application of stereotactic methods of radiotherapy -SBRT), where the survival period varies between a few months and more than one year (12 months).…”

Section: Introductionmentioning

confidence: 99%

“…The latter method comprises the use of anti-CTLA-4 antibodies against cytotoxic antigen-4 of T lymphocytes (iplimumab) or BRAF receptor serine/threonine protein kinase inhibitors (wemurafenib, dabrafenib). However, the effectiveness of systemic treatment is here limited; this concerns both chemotherapy and immunotherapy and cases of MBM in patients without any symptoms or whose symptoms are very limited [2,4,12,[23][24][25][26][27][28][29].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The effectiveness of brain metastases radiotherapy in patients with melanoma

Szyszka-Charewicz

2017

Nowotwory. Journal of Oncology

View full text Add to dashboard Cite

Introduction. Melanoma gives rise to 7-13% brain metastases (MBM -melanoma brain metastases) and is ranked third leading cause of brain metastases. The prognosis of patients with MBM is poor, with a median survival time of 3-6 months. Assessment of the value and limitations of three prognostic scores used in patients with melanoma brain metastases (MBM) was presented in this paper. Material and methods. In 110 patients with MBM, we executed an analysis of prognostic factors. All patients were treated with radiotherapy: whole brain radiotherapy performed as a treatment method in combination with chemotherapy (14 patients -12.7%), neurosurgery (12 patients -10.9% or stereotactic radiosurgery (8 patients -7.3%). Results. The median overall survival (OS) from diagnosis MBM was 4.8 months (95% CI 4.1-5.2 months). The analyses showed that the Karnofsky Performance Status and number of the MBM are independent significant prognostic factors. The analyses of OS, as a function of prognostic scores, showed that in the class with the best prognosis median OS was similar (7.2-10.7 months); and in the class with the worse prognosis median OS was also similar (range, 2.6-4.3 months). Conclusions. Our observations and data from literature showed that the presented scores can: distinguish classes of patients by prognosis before treatment, guide the choice of treatment methods and help design strategies for patient selection in clinical trials but they did not fully discriminate between unfavourable groups. NOWOTWORY J Oncol 2016; 66, 5: 367-374

show abstract